ライフサイエンスコーパス: mitral valve replacement

1 e, ranging from 9.9% (nephrectomy) to 22.2% (mitral valve replacement).

2 r was 4.8% (2.1-9.0) and 6.8% (2.9-10.1) for mitral valve replacement.

3 ally in the forthcoming era of transcatheter mitral valve replacement.

4 rwent mechanical prosthetic vs bioprosthetic mitral valve replacement.

5 Bioprosthetic vs mechanical prosthetic mitral valve replacement.

6 tnatal intervention; 42% underwent aortic or mitral valve replacement.

7 oup at high or extreme risk for conventional mitral valve replacement.

8 pass grafting, aortic valve replacement, and mitral valve replacement.

9 d to either total or partial chordal-sparing mitral valve replacement.

10 tly, most of these patients are referred for mitral valve replacement.

11 red to the standard operation for aortic and mitral valve replacement.

12 od for treating severe mitral regurgitation--mitral valve replacement.

13 mitral-valve repair and those who underwent mitral-valve replacement.

14 alve replacement and from 16.8% to 53.7% for mitral-valve replacement.

15 aortic valve replacement (0.73 versus 0.76), mitral valve replacement (0.73 versus 0.74), and abdomin

16 valve replacement) (228, 5.9%), CABG + MVR (mitral valve replacement) (35, 0.9%), AVR (231, 6%), MVR

17 eat percutaneous mitral balloon valvotomy or mitral valve replacement (78 +/- 6% vs. 67 +/- 8%, p = 0

18 eat percutaneous mitral balloon valvotomy or mitral valve replacement (86 +/- 4% vs. 40 +/- 4%) and f

19 ower survival rate and a higher incidence of mitral valve replacement and all end points combined.

20 mitral valve repair is far more complex than mitral valve replacement and must be accompanied by care

21 replacement (TMVR) for patients with failed mitral valve replacement and repair.

22 il 70 years of age among patients undergoing mitral-valve replacement and until 55 years of age among

23 dverse clinical events (death, repeat PMC or mitral valve replacement) and functional status was asse

24 s, 75% had aortic valve replacement, 20% had mitral valve replacement, and 5% had both.

25 procedures (CABG, aortic valve replacement, mitral valve replacement, and elective abdominal aortic

26 mitral valve in 4 of 4 patients (100%) after mitral valve replacement, and in the subaortic region in

27 tral valve repair in 2; and septal myectomy, mitral valve replacement, aortoplasty, subaortic stenosi

28 derwent isolated aortic valve replacement or mitral valve replacement at Dartmouth-Hitchcock Medical

29 at percutaneous mitral balloon valvotomy and mitral valve replacement at follow-up.

30 cement (CABG/AVR), and 18.2% after CABG with mitral valve replacement (CABG/MVR).

31 In patients undergoing aortic-valve or mitral-valve replacement, either a mechanical or biologi

32 +/- 6.10 micrograms/mg tissue) and in sheep mitral valve replacements (ethanol-pretreated calcium le

33 f retaining the subvalvular apparatus during mitral valve replacement for chronic mitral regurgitatio

34 n of mitral valve reconstruction rather than mitral valve replacement for mitral insufficiency second

35 A three-yr-old girl was admitted after mitral valve replacement for persistent severe mitral in

36 increased substantially for aortic-valve and mitral-valve replacement, from 11.5% to 51.6% for aortic

37 but longer for other procedures (aortic and mitral valve replacement, gastrectomy).

38 and stentless "freehand" bileaflet xenograft mitral valve replacement has arisen.

39 Clinical and experimental studies of mitral valve replacement have shown a depression of vent

40 e repairs, risks and benefits (compared with mitral valve replacement) have become better defined.

41 ting in 95%, mitral valve repair in 22%, and mitral valve replacement in 1%.

42 ; mitral valve replacement in 18; prosthetic mitral valve replacement in 14; repair of prosthetic mit

43 cement was performed in 3415 patients (58%), mitral valve replacement in 1848 patients (32%), and com

44 included mitral valve repair in 27 patients; mitral valve replacement in 18; prosthetic mitral valve

45 1848 patients (32%), and combined aortic and mitral valve replacement in 562 patients (10%).

46 valve replacement in 3 and valvectomy in 7, mitral valve replacement in 6 and repair in 1, aortic va

47 50-69 years) who underwent primary, isolated mitral valve replacement in New York State hospitals fro

48 mong patients aged 50 to 69 years undergoing mitral valve replacement in New York State, there was no

49 zed trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemi

50 Advantages over mitral valve replacement include improved hemodynamic pe

51 Advantages over mitral valve replacement include improved hemodynamic pe

52 rrent status of allograft use for aortic and mitral valve replacement is reviewed.

53 Transcatheter mitral valve replacement is still in early development.

54 though these findings suggest bioprosthetic mitral valve replacement may be a reasonable alternative

55 Previous studies in patients undergoing mitral valve replacement may not be applicable in the pr

56 air and 60.6+/-39.0 ml per square meter with mitral-valve replacement (mean changes from baseline, -9

57 g isolated aortic valve replacement (AVR) or mitral valve replacement (MVR) and from 43,463 patients

58 ing single aortic valve replacement (AVR) or mitral valve replacement (MVR) at 13 VA medical centers

59 essed using data from 21 patients undergoing mitral valve replacement (MVR) for chronic MR.

60 Mitral valve replacement (MVR) has a high mortality and

61 Chordal excision during mitral valve replacement (MVR) impairs left ventricular

62 d functional status after initial mechanical mitral valve replacement (MVR) in children <5 years of a

63 ort- and long-term outcomes after prosthetic mitral valve replacement (MVR) in children aged <5 years

64 surgical options for IMR and to discuss when mitral valve replacement (MVR) may be favored over mitra

65 tic valve replacement (AVR) and 482 isolated mitral valve replacement (MVR) operations with the St Ju

66 Early attempts at mitral valve replacement (MVR) with mitral valve allogra

67 Recent studies have suggested that mitral valve replacement (MVR) with sparing of the subva

68 ), surgical mitral valvuloplasty (SMVP), and mitral valve replacement (MVR), although the optimal the

69 In younger patients requiring mitral valve replacement (MVR), mechanical prostheses (M

70 ) in such patients are few; the alternative, mitral valve replacement (MVR), necessitates commitment

71 ibrillation (AF) in patients with mechanical mitral valve replacement (MVR).

72 dity after aortic valve replacement (AVR) or mitral valve replacement (MVR).

73 Four late deaths occurred after elective mitral valve replacement (MVR).

74 d with structural valve deterioration (SVD) (mitral valve replacement [MVR] > AVR) and, therefore, fo

75 ral valve replacement [MVRm], 216 biological mitral valve replacement [MVRb]), thromboembolic complic

76 p] and 447 valve replacement: 231 mechanical mitral valve replacement [MVRm], 216 biological mitral v

77 ty, consisting of cleft repair (n = 10), and mitral valve replacement (n = 2) were performed selectiv

78 cedures were high risk, with an STS PROM for mitral valve replacement of 11%.

79 mean+/-SD, 70+/-12), and none had associated mitral valve replacement or evidence of mitral stenosis:

80 Mitral valve replacement or repair may be complicated by

81 , 0.90 (0.86-0.93) compared to dysfunctional mitral valve replacement or repair, 0.78 (0.70-0.90), P

82 t, 0.78 (0.73-0.87), P < .001, as did normal mitral valve replacement or repair, 0.90 (0.86-0.93) com

83 85 (74-96) seconds compared to dysfunctional mitral valve replacement or repair, 143 (128-192) second

84 ement, 36 patients with normally functioning mitral valve replacement or repair, 19 patients with dys

85 , P < .001, and also in normally functioning mitral valve replacement or repair, 85 (74-96) seconds c

86 nt or repair, 19 patients with dysfunctional mitral valve replacement or repair, and 31 patients with

87 erative mortality in the patients undergoing mitral valve replacement or repair.

88 e replacements and in 14 of 19 dysfunctional mitral valve replacements or repairs (P < .001 for both)

89 tic valve replacements and in 2 of 36 normal mitral valve replacements or repairs but were abnormal i

90 that was unassociated with mitral stenosis, mitral valve replacement, or a previous operation involv

91 and Kaplan-Meier estimates in two series of mitral valve replacement patients: thromboembolism in a

92 Supraannular mitral valve replacement provides relief of mitral steno

93 Among patients who underwent mitral-valve replacement, receipt of a biologic prosthes

94 bstantially, whereas the mortality rate from mitral valve replacement remained high, largely because

95 operation than do males and patients having mitral valve replacements, respectively.

96 etention of the subvalvular apparatus during mitral valve replacement resulted in improved ejection p

97 Results from the use of St Jude mitral valve replacement (SJMVR) were compared with thos

98 n) and without associated mitral stenosis or mitral valve replacement strongly suggest that an underl

99 compared to control valve implants in sheep mitral valve replacement studies.

100 ormance of the Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Risk Patients wi

101 of failure using allograft mitral valves for mitral valve replacement, the technical problems of papi

102 Limited data exist regarding transcatheter mitral valve replacement (TMVR) for patients with failed

103 More recently, transcatheter mitral valve replacement (TMVR) has emerged as a potenti

104 Transcatheter mitral valve replacement (TMVR) is a potential therapy f

105 Transcatheter mitral valve replacement (TMVR) may be an option for sel

106 e are scarce data available on transcatheter mitral valve replacement (TMVR), and these have been lim

107 Mean time from mitral valve replacement to percutaneous PVL repair was

108 PCr/ATP in those referred for mitral valve replacement was lower (n=8, 1.17+/-0.23) al

109 for elective isolated or combined aortic and mitral valve replacement were included.

110 , diabetes mellitus, and combined aortic and mitral valve replacement were the strongest predictors o

111 nderwent primary aortic-valve replacement or mitral-valve replacement with a mechanical or biologic p

112 patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and thos